Tuesday, August 19, 2025 10:35:56 AM
Rip, so you're saying Perceptive has ownership of IOVA but now in a different fund? Or basically, has moved his positions to different funds for whatever reason (possibly even future tax implications)?
FWIW, there's a few notable increased positions in IOVA. This one caught my eye of 9.3 million shares. Just a little food for thought (pulled from Fintel):
"Millennium Management Llc ownership in IOVA / Iovance Biotherapeutics, Inc.
On August 14, 2025 - Millennium Management Llc filed a 13F-HR form disclosing ownership of 9,330,223 shares of Iovance Biotherapeutics, Inc. (US:IOVA) valued at $16,047,984 USD as of June 30, 2025. The entity filed a previous 13F-HR on May 15, 2025 disclosing 158,323 shares of Iovance Biotherapeutics, Inc.. This represents a change in shares of 5,793.16% during the quarter. The current value of the position is $23,325,558 USD."
Also, Bank of America is now at over 4 million shares and Morgan Stanley has increased to over 6.4 million.
I know that many passive funds have internal investing parameters, but still worth noting.
GL IOVA longs.
FWIW, there's a few notable increased positions in IOVA. This one caught my eye of 9.3 million shares. Just a little food for thought (pulled from Fintel):
"Millennium Management Llc ownership in IOVA / Iovance Biotherapeutics, Inc.
On August 14, 2025 - Millennium Management Llc filed a 13F-HR form disclosing ownership of 9,330,223 shares of Iovance Biotherapeutics, Inc. (US:IOVA) valued at $16,047,984 USD as of June 30, 2025. The entity filed a previous 13F-HR on May 15, 2025 disclosing 158,323 shares of Iovance Biotherapeutics, Inc.. This represents a change in shares of 5,793.16% during the quarter. The current value of the position is $23,325,558 USD."
Also, Bank of America is now at over 4 million shares and Morgan Stanley has increased to over 6.4 million.
I know that many passive funds have internal investing parameters, but still worth noting.
GL IOVA longs.
Recent IOVA News
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/22/2026 09:15:00 PM
- Iovance Biotherapeutics to Present at Upcoming Conference • GlobeNewswire Inc. • 05/21/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 01:18:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:16:23 PM
- Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates • GlobeNewswire Inc. • 05/07/2026 11:05:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/01/2026 09:00:21 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 09:05:17 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 09:01:20 PM
- Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 • GlobeNewswire Inc. • 04/27/2026 12:01:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/17/2026 09:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 09:01:25 PM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (Canada) • 04/01/2026 12:49:00 AM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (US) • 04/01/2026 12:49:00 AM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (US) • 03/24/2026 02:00:00 PM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (Canada) • 03/24/2026 02:00:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2026 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 09:25:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:02:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:12 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (Canada) • 03/05/2026 02:00:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (US) • 03/05/2026 02:00:00 PM
